STUDY TITLE: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

NCT07071961

This is a Phase 2 study to assess the effects of Regorafenib and Lorigerlimab on ctDNA in CRC patient with MRD after completing standard-of-care therapy.

Status: Not yet Recruiting

Key Eligibility Criteria

  • Patients with confirmed stage II-IV colon or rectal cancer
  • Patients must:
    • have completed all planned adjuvant therapies
    • have no radiographic evidence of disease within 28 days of positive ctDNA assay
    • have confirmed ctDNA positive assay prior to starting study therapy

Treatment

Drug: Regorafenib, a kinase inhibitor

Drug: Lorigerlimab, a PD-1 and CTLA-4 inhibitor

Study Plan